Press Releases

MYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch

Download PDF

10-K filing and highlights of CEO Mannello's first seven months also to be discussed

CEDAR KNOLLS, N.J., March 31, 2017 /PRNewswire/ --

Interested parties may access the call as follows:

Event Title:  Management Highlights
Event Date: 4/4/17
Event Time: 11:00 AM EDT

Live Participant Dial-In:                  

US & Canada:           877-407-8309
International:             201-689-8057


       Webcast URL:


MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company focused on developing products that build muscle and improve muscle health and performance, will file its Annual Report on Form 10-K for the year ended December 31, 2016 (the "Form 10-K") with the Securities and Exchange Commission on Friday, March 31, 2017. The Form 10-K will be accessible via the 'SEC Filings' page of the Investor Relations section of the Company's corporate web site at on that date.

Moderated by CEO Joseph Mannello, the call will focus on the launch of the Qurr product line (, and will highlight significant developments of the last seven months.  Participants will have the opportunity to ask questions or comment following the presentation.


About MYOS RENS Technology Inc.
MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and brings them to market. MYOS is the owner of Fortetropin®, the world's first clinically demonstrated myostatin reducer (myostatin is a natural regulatory protein, which inhibits muscle growth). Fortetropin® is manufactured through a proprietary process which retains its biological activity.  MYOS believes that Fortetropin® has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYOS and its proprietary ingredient, Fortetropin®, visit

About Qurr
The Qurr product series is the Company's newly-branded line of muscle health products.  These all-natural, non-GMO products contain Fortetropin®, an egg-based, all natural myostatin reducer clinically proven to build healthy muscle. Qurr products can be ordered by visiting The Qurr product line is owned and sold directly by the Company through and

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of our products, including Qurr products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

MYOS Corporation Investor and Media Contact:
MYOS Corporation
Joanne Goodford
(973) 509-0444

To view the original version on PR Newswire, visit: